Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Impact · against what's priced in

The article provides no new catalysts for JNJ or BMY, as the financial figures cited are already reflected in current valuations. JNJ's growth trajectory and BMY's recovery to profitability are historical FY2025 data points already factored into the market price.

JNJ+0.00

Already priced in

The price assumes

raised 2026 revenue guidance... and adjusted EPS... which simply confirmed the recent 6.0% to 6.6% growth trajectory